欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

美國Achaogen
2002年，羅姆斯伯格的實驗室剛開始獲得以上結果時，他就發現了一種潛在的藥物——能和抗生素一起服用的小分子藥物，該藥物可以阻止LexA受到剪切。他與兩個合伙人毫不費力就籌集到1500萬美元，開辦了一家名叫Achaogen的公司(“Achao”的意思是“抵制混亂”——并由一位投資者添加上“gen”，因為名稱中具有這個后綴的公司，其發展往往會一帆風順)。
Achaogen (a-KAY-o-jen) develops small molecule therapeutics to treat multi-drug resistant bacterial infections, a serious unmet medical need causing hundreds of thousands of deaths worldwide each year.

Achaogen is developing next-generation aminoglycosides: “neoglycosides”— a designation that reflects their lineage and conveys their novelty. Achaogen’s lead neoglycosides display broad-spectrum activity against many resistant bacteria that cause systemic infections, including K. pneumoniae, E. coli and MRSA.

Our world-class team has led or participated in the development of several approved and/or late-stage antibacterial compounds, and our scientific advisors include U.S. and European thought leaders in antimicrobial resistance and drug development. We focus these resources on the tasks of compound discovery, lead optimization, and early-stage clinical trials, while leveraging external resources worldwide for screening and hit generation and for later-stage clinical work. This maximizes our capital efficiency, minimizing infrastructure costs while mitigating the risks and costs of late phase trials.

Our state-of-the-art research facility is located on the shores of the San Francisco Bay, five minutes from the San Francisco International Airport, and only fifteen minutes from downtown San Francisco.